Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.

Authors

Yonggui Hong

Anyang Cancer Hospital, Anyang, China

Yonggui Hong , Tao Wu , Ping Lu , Zhiwei Chang , Wei Liang , Guifang Zhang , Junsheng Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04966611

DOI

10.1200/JCO.2022.40.4_suppl.320

Abstract #

320

Poster Bd #

Online Only

Abstract Disclosures

FEATURED

Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.

Authors

Yonggui Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.

Poster

Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study.

Poster

A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.

Poster

Efficacy and safety of anlotinib with or without PD-1 blockades in the treatment of advanced primary hepatocellular carcinoma (HCC): A real-world exploratory study.